Travere Operating Income from 2010 to 2024

TVTX Stock

USD 19.57 0.76 4.04%

Travere Therapeutics Operating Income yearly trend continues to be fairly stable with very little volatility. Operating Income is likely to outpace its year average in 2024. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Travere Therapeutics generates from its operations. View All Fundamentals

Operating Income

First Reported

2010-09-30

Previous Quarter

-67.1 M

Current Value

-54.8 M

Quarterly Volatility

31.6 M

Credit Downgrade

Yuan Drop

Covid

Check Travere Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Travere Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 16.4 M, Selling General Administrative of 278.8 M or Other Operating Expenses of 548.1 M, as well as many indicators such as Price To Sales Ratio of 6.88, Dividend Yield of 0.0 or PTB Ratio of 3.16. Travere financial statements analysis is a perfect complement when working with Travere Therapeutics Valuation or Volatility modules.

Check out the analysis of Travere Therapeutics Correlation against competitors.

For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.

Latest Travere Therapeutics' Operating Income Growth Pattern

Below is the plot of the Operating Income of Travere Therapeutics over the last few years. Operating Income is the amount of profit realized from Travere Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Travere Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Travere Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Travere Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Travere Operating Income Regression Statistics

	Arithmetic Mean	(111,849,456)
	Coefficient Of Variation	(107.89)
	Mean Deviation	90,442,397
	Median	(75,377,000)
	Standard Deviation	120,679,271
	Sample Variance	14563.5T
	Range	376.7M
	R-Value	(0.85)
	Mean Square Error	4286.3T
	R-Squared	0.73
	Significance	0.000054
	Slope	(23,003,645)
	Total Sum of Squares	203888.8T

Travere Operating Income History

	2024	-357.9 M
	2023	-376.7 M
	2022	-251.6 M
	2021	-139.5 M
	2020	-75.4 M
	2019	-99.8 M
	2018	-80 M

Other Fundumenentals of Travere Therapeutics

Non Operating Income Net Other

Travere Therapeutics Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Intangible Assets	Short Term Investments	Net Receivables	Good Will	Net Tangible Assets	Long Term Debt	Net Invested Capital	Net Working Capital	Property Plant Equipment	Short Long Term Debt	Capital Stock	Long Term Debt Total	Capital Surpluse
Total Assets		0.8	0.54	-0.68	0.6	0.85	0.99	0.2	0.94	0.2	0.86	0.96	0.39	-0.29	-0.35	0.72	0.72	0.74	0.37	-0.19	0.59	-0.19	0.53
Total Stockholder Equity	0.8		0.06	-0.22	0.34	0.46	0.75	0.28	0.63	0.49	0.85	0.67	0.6	-0.06	0.09	0.22	0.44	0.42	0.17	-0.07	0.15	-0.07	0.12
Net Debt	0.54	0.06		-0.94	0.79	0.88	0.59	-0.1	0.63	-0.37	0.28	0.71	-0.05	-0.79	-0.91	0.92	0.74	0.74	0.37	-0.69	0.84	-0.69	0.82
Retained Earnings	-0.68	-0.22	-0.94		-0.83	-0.94	-0.73	0.12	-0.78	0.33	-0.38	-0.8	0.03	0.75	0.82	-0.94	-0.8	-0.84	-0.49	0.64	-0.94	0.64	-0.9
Accounts Payable	0.6	0.34	0.79	-0.83		0.81	0.62	0.0	0.66	-0.19	0.43	0.71	0.05	-0.85	-0.76	0.72	0.69	0.68	0.26	-0.8	0.73	-0.8	0.75
Total Liab	0.85	0.46	0.88	-0.94	0.81		0.87	0.08	0.88	-0.09	0.66	0.91	0.15	-0.62	-0.71	0.92	0.81	0.84	0.44	-0.54	0.81	-0.54	0.77
Total Current Assets	0.99	0.75	0.59	-0.73	0.62	0.87		0.1	0.93	0.1	0.78	0.98	0.31	-0.34	-0.39	0.78	0.78	0.81	0.37	-0.22	0.66	-0.22	0.61
Short Term Debt	0.2	0.28	-0.1	0.12	0.0	0.08	0.1		0.22	0.74	0.5	0.04	0.29	0.07	0.16	-0.19	-0.08	-0.12	-0.3	0.06	-0.18	0.06	-0.12
Common Stock	0.94	0.63	0.63	-0.78	0.66	0.88	0.93	0.22		0.14	0.76	0.92	0.35	-0.39	-0.49	0.77	0.68	0.72	0.43	-0.25	0.72	-0.25	0.66
Current Deferred Revenue	0.2	0.49	-0.37	0.33	-0.19	-0.09	0.1	0.74	0.14		0.5	0.01	0.46	0.24	0.36	-0.36	-0.17	-0.23	-0.38	0.2	-0.35	0.2	-0.28
Intangible Assets	0.86	0.85	0.28	-0.38	0.43	0.66	0.78	0.5	0.76	0.5		0.72	0.54	-0.08	-0.14	0.37	0.4	0.4	0.23	-0.09	0.2	-0.09	0.16
Short Term Investments	0.96	0.67	0.71	-0.8	0.71	0.91	0.98	0.04	0.92	0.01	0.72		0.25	-0.46	-0.52	0.86	0.84	0.85	0.35	-0.33	0.72	-0.33	0.68
Net Receivables	0.39	0.6	-0.05	0.03	0.05	0.15	0.31	0.29	0.35	0.46	0.54	0.25		0.01	0.01	-0.06	-0.09	-0.1	0.14	0.0	-0.03	0.0	-0.07
Good Will	-0.29	-0.06	-0.79	0.75	-0.85	-0.62	-0.34	0.07	-0.39	0.24	-0.08	-0.46	0.01		0.81	-0.61	-0.62	-0.56	-0.2	0.95	-0.74	0.95	-0.78
Net Tangible Assets	-0.35	0.09	-0.91	0.82	-0.76	-0.71	-0.39	0.16	-0.49	0.36	-0.14	-0.52	0.01	0.81		-0.78	-0.46	-0.45	-0.3	0.69	-0.75	0.69	-0.74
Long Term Debt	0.72	0.22	0.92	-0.94	0.72	0.92	0.78	-0.19	0.77	-0.36	0.37	0.86	-0.06	-0.61	-0.78		0.83	0.85	0.46	-0.46	0.87	-0.46	0.82
Net Invested Capital	0.72	0.44	0.74	-0.8	0.69	0.81	0.78	-0.08	0.68	-0.17	0.4	0.84	-0.09	-0.62	-0.46	0.83		0.98	0.35	-0.54	0.76	-0.54	0.75
Net Working Capital	0.74	0.42	0.74	-0.84	0.68	0.84	0.81	-0.12	0.72	-0.23	0.4	0.85	-0.1	-0.56	-0.45	0.85	0.98		0.36	-0.49	0.81	-0.49	0.79
Property Plant Equipment	0.37	0.17	0.37	-0.49	0.26	0.44	0.37	-0.3	0.43	-0.38	0.23	0.35	0.14	-0.2	-0.3	0.46	0.35	0.36		-0.18	0.47	-0.18	0.24
Short Long Term Debt	-0.19	-0.07	-0.69	0.64	-0.8	-0.54	-0.22	0.06	-0.25	0.2	-0.09	-0.33	0.0	0.95	0.69	-0.46	-0.54	-0.49	-0.18		-0.59	1.0	-0.64
Capital Stock	0.59	0.15	0.84	-0.94	0.73	0.81	0.66	-0.18	0.72	-0.35	0.2	0.72	-0.03	-0.74	-0.75	0.87	0.76	0.81	0.47	-0.59		-0.59	0.97
Long Term Debt Total	-0.19	-0.07	-0.69	0.64	-0.8	-0.54	-0.22	0.06	-0.25	0.2	-0.09	-0.33	0.0	0.95	0.69	-0.46	-0.54	-0.49	-0.18	1.0	-0.59		-0.64
Capital Surpluse	0.53	0.12	0.82	-0.9	0.75	0.77	0.61	-0.12	0.66	-0.28	0.16	0.68	-0.07	-0.78	-0.74	0.82	0.75	0.79	0.24	-0.64	0.97	-0.64

Click cells to compare fundamentals

About Travere Therapeutics Financial Statements

Travere Therapeutics investors use historical fundamental indicators, such as Travere Therapeutics' Operating Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Travere Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	-376.7 M	-357.9 M
Non Operating Income Net Other	-295.2 K	-280.4 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

Additional Tools for Travere Stock Analysis

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Travere Operating Income from 2010 to 2024

Latest Travere Therapeutics' Operating Income Growth Pattern

Travere Operating Income Regression Statistics

Travere Operating Income History

Other Fundumenentals of Travere Therapeutics

Travere Therapeutics Operating Income component correlations

About Travere Therapeutics Financial Statements

Also Currently Popular

Additional Tools for Travere Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY